#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Lício Velloso
1-1	0-5	Lício	person[1]	new[1]	coref	4-1[8_1]
1-2	6-13	Velloso	person[1]	new[1]	_	_

#Text=Licio Augusto Velloso is a Brazilian full professor of medicine at the University of Campinas .
2-1	14-19	Licio	person[2]	new[2]	coref	2-5[3_2]
2-2	20-27	Augusto	person[2]	new[2]	_	_
2-3	28-35	Velloso	person[2]	new[2]	_	_
2-4	36-38	is	_	_	_	_
2-5	39-40	a	person[3]	giv[3]	_	_
2-6	41-50	Brazilian	person[3]	giv[3]	_	_
2-7	51-55	full	person[3]	giv[3]	_	_
2-8	56-65	professor	person[3]	giv[3]	_	_
2-9	66-68	of	person[3]	giv[3]	_	_
2-10	69-77	medicine	person[3]|abstract	giv[3]|new	_	_
2-11	78-80	at	person[3]	giv[3]	_	_
2-12	81-84	the	person[3]|organization[5]	giv[3]|new[5]	coref	4-10[13_5]
2-13	85-95	University	person[3]|organization[5]	giv[3]|new[5]	_	_
2-14	96-98	of	person[3]|organization[5]	giv[3]|new[5]	_	_
2-15	99-107	Campinas	person[3]|organization[5]|place	giv[3]|new[5]|new	coref	4-13
2-16	108-109	.	_	_	_	_

#Text=Education
3-1	110-119	Education	abstract	new	_	_

#Text=Lício Velloso obtained his MD degree in 1986 from the University of Campinas .
4-1	120-125	Lício	person[8]	giv[8]	ana	4-4[0_8]
4-2	126-133	Velloso	person[8]	giv[8]	_	_
4-3	134-142	obtained	_	_	_	_
4-4	143-146	his	person|abstract[11]	giv|new[11]	ana	5-1
4-5	147-149	MD	abstract|abstract[11]	new|new[11]	_	_
4-6	150-156	degree	abstract[11]	new[11]	_	_
4-7	157-159	in	_	_	_	_
4-8	160-164	1986	time	new	_	_
4-9	165-169	from	_	_	_	_
4-10	170-173	the	organization[13]	giv[13]	coref	6-25[43_13]
4-11	174-184	University	organization[13]	giv[13]	_	_
4-12	185-187	of	organization[13]	giv[13]	_	_
4-13	188-196	Campinas	organization[13]|place	giv[13]|giv	coref	5-28
4-14	197-198	.	_	_	_	_

#Text=He then attended Uppsala University in Sweden from which he graduated in 1993 and then served as a postdoc at the Mario Saad Lab , University of Campinas and at the Ron Kahn Lab , Harvard University in 1994 and 1995 respectively . [ 1 ]
5-1	199-201	He	person	giv	ana	5-10
5-2	202-206	then	_	_	_	_
5-3	207-215	attended	_	_	_	_
5-4	216-223	Uppsala	place|organization[17]	new|new[17]	_	_
5-5	224-234	University	organization[17]	new[17]	_	_
5-6	235-237	in	organization[17]	new[17]	_	_
5-7	238-244	Sweden	organization[17]|place[18]	new[17]|new[18]	_	_
5-8	245-249	from	organization[17]|place[18]	new[17]|new[18]	_	_
5-9	250-255	which	organization[17]|place[18]	new[17]|new[18]	_	_
5-10	256-258	he	organization[17]|place[18]|person	new[17]|new[18]|giv	ana	6-1
5-11	259-268	graduated	organization[17]|place[18]	new[17]|new[18]	_	_
5-12	269-271	in	organization[17]|place[18]	new[17]|new[18]	_	_
5-13	272-276	1993	organization[17]|place[18]|time	new[17]|new[18]|new	_	_
5-14	277-280	and	_	_	_	_
5-15	281-285	then	_	_	_	_
5-16	286-292	served	_	_	_	_
5-17	293-295	as	_	_	_	_
5-18	296-297	a	person[21]	new[21]	_	_
5-19	298-305	postdoc	person[21]	new[21]	_	_
5-20	306-308	at	person[21]	new[21]	_	_
5-21	309-312	the	person[21]|organization[22]	new[21]|new[22]	appos	5-26[23_22]
5-22	313-318	Mario	person[21]|organization[22]	new[21]|new[22]	_	_
5-23	319-323	Saad	person[21]|organization[22]	new[21]|new[22]	_	_
5-24	324-327	Lab	person[21]|organization[22]	new[21]|new[22]	_	_
5-25	328-329	,	_	_	_	_
5-26	330-340	University	organization[23]	giv[23]	coref	5-31[25_23]
5-27	341-343	of	organization[23]	giv[23]	_	_
5-28	344-352	Campinas	organization[23]|place	giv[23]|giv	coref	6-28
5-29	353-356	and	_	_	_	_
5-30	357-359	at	_	_	_	_
5-31	360-363	the	organization[25]	giv[25]	appos	5-36[27_25]
5-32	364-367	Ron	organization[25]	giv[25]	_	_
5-33	368-372	Kahn	organization[25]	giv[25]	_	_
5-34	373-376	Lab	organization[25]	giv[25]	_	_
5-35	377-378	,	_	_	_	_
5-36	379-386	Harvard	organization|organization[27]	new|giv[27]	_	_
5-37	387-397	University	organization[27]	giv[27]	_	_
5-38	398-400	in	organization[27]	giv[27]	_	_
5-39	401-405	1994	organization[27]|time	giv[27]|new	_	_
5-40	406-409	and	organization[27]	giv[27]	_	_
5-41	410-414	1995	organization[27]|time	giv[27]|new	_	_
5-42	415-427	respectively	_	_	_	_
5-43	428-429	.	_	_	_	_
5-44	430-431	[	_	_	_	_
5-45	432-433	1	abstract	new	_	_
5-46	434-435	]	_	_	_	_

#Text=He also was postdoctoral fellow at the Joslin Diabetes Center [ 2 ] and is coordinator of the Obesity and Comorbidities Research Center at the University of Campinas . [ 3 ]
6-1	436-438	He	person	giv	coref	6-4[32_0]
6-2	439-443	also	_	_	_	_
6-3	444-447	was	_	_	_	_
6-4	448-460	postdoctoral	person[32]|person[33]	giv[32]|giv[33]	coref|ana	6-4[33_32]|8-3[0_33]
6-5	461-467	fellow	person[32]|person[33]	giv[32]|giv[33]	_	_
6-6	468-470	at	person[32]|person[33]	giv[32]|giv[33]	_	_
6-7	471-474	the	person[32]|person[33]|organization[36]	giv[32]|giv[33]|new[36]	coref	6-18[42_36]
6-8	475-481	Joslin	person[32]|person[33]|person|organization[36]	giv[32]|giv[33]|new|new[36]	_	_
6-9	482-490	Diabetes	person[32]|person[33]|abstract|organization[36]	giv[32]|giv[33]|new|new[36]	coref	16-13
6-10	491-497	Center	person[32]|person[33]|organization[36]	giv[32]|giv[33]|new[36]	_	_
6-11	498-499	[	person[33]	giv[33]	_	_
6-12	500-501	2	person[33]|abstract	giv[33]|new	_	_
6-13	502-503	]	person[33]	giv[33]	_	_
6-14	504-507	and	person[33]	giv[33]	_	_
6-15	508-510	is	person[33]	giv[33]	_	_
6-16	511-522	coordinator	person[33]|person[38]	giv[33]|new[38]	_	_
6-17	523-525	of	person[33]|person[38]	giv[33]|new[38]	_	_
6-18	526-529	the	person[33]|person[38]|organization[42]	giv[33]|new[38]|giv[42]	_	_
6-19	530-537	Obesity	person[33]|person[38]|abstract|organization[42]	giv[33]|new[38]|new|giv[42]	coref	9-5[59_0]
6-20	538-541	and	person[33]|person[38]|organization[42]	giv[33]|new[38]|giv[42]	_	_
6-21	542-555	Comorbidities	person[33]|person[38]|person|organization[42]	giv[33]|new[38]|new|giv[42]	_	_
6-22	556-564	Research	person[33]|person[38]|abstract|organization[42]	giv[33]|new[38]|new|giv[42]	coref	7-1
6-23	565-571	Center	person[33]|person[38]|organization[42]	giv[33]|new[38]|giv[42]	_	_
6-24	572-574	at	person[33]|person[38]|organization[42]	giv[33]|new[38]|giv[42]	_	_
6-25	575-578	the	person[33]|person[38]|organization[42]|organization[43]	giv[33]|new[38]|giv[42]|giv[43]	_	_
6-26	579-589	University	person[33]|person[38]|organization[42]|organization[43]	giv[33]|new[38]|giv[42]|giv[43]	_	_
6-27	590-592	of	person[33]|person[38]|organization[42]|organization[43]	giv[33]|new[38]|giv[42]|giv[43]	_	_
6-28	593-601	Campinas	person[33]|person[38]|organization[42]|organization[43]|place	giv[33]|new[38]|giv[42]|giv[43]|giv	_	_
6-29	602-603	.	_	_	_	_
6-30	604-605	[	_	_	_	_
6-31	606-607	3	abstract	new	coref	22-49
6-32	608-609	]	_	_	_	_

#Text=Research
7-1	610-618	Research	abstract	giv	coref	20-1[126_0]

#Text=In 2001 he studied type 2 diabetes along with Claudio Teodoro de Souza , a back-then Ph.D. student at the Cell Signaling Laboratory .
8-1	619-621	In	_	_	_	_
8-2	622-626	2001	time	new	_	_
8-3	627-629	he	person	giv	coref	10-3[64_0]
8-4	630-637	studied	abstract	new	coref|none	22-17[153_0]|8-4[0_153]
8-5	638-642	type	abstract[49]|abstract[50]	new[49]|new[50]	coref	21-24[0_50]
8-6	643-644	2	abstract[49]|abstract[50]	new[49]|new[50]	_	_
8-7	645-653	diabetes	abstract[50]	new[50]	_	_
8-8	654-659	along	_	_	_	_
8-9	660-664	with	_	_	_	_
8-10	665-672	Claudio	person[51]	new[51]	appos	8-15[53_51]
8-11	673-680	Teodoro	person[51]	new[51]	_	_
8-12	681-683	de	person[51]	new[51]	_	_
8-13	684-689	Souza	person[51]	new[51]	_	_
8-14	690-691	,	_	_	_	_
8-15	692-693	a	person[53]	giv[53]	coref	13-6[0_53]
8-16	694-703	back-then	abstract[52]|person[53]	new[52]|giv[53]	_	_
8-17	704-709	Ph.D.	abstract[52]|person[53]	new[52]|giv[53]	_	_
8-18	710-717	student	person[53]	giv[53]	_	_
8-19	718-720	at	person[53]	giv[53]	_	_
8-20	721-724	the	person[53]|organization[56]	giv[53]|new[56]	_	_
8-21	725-729	Cell	person[53]|person|object[55]|organization[56]	giv[53]|new|new[55]|new[56]	_	_
8-22	730-739	Signaling	person[53]|object[55]|organization[56]	giv[53]|new[55]|new[56]	_	_
8-23	740-750	Laboratory	person[53]|organization[56]	giv[53]|new[56]	_	_
8-24	751-752	.	_	_	_	_

#Text=Their study revealed that the disease reoccurs when pancreas fail to supply the peripheral need for insulin that the body needs .
9-1	753-758	Their	person|abstract[58]	acc|new[58]	coref	18-2[116_58]
9-2	759-764	study	abstract[58]	new[58]	_	_
9-3	765-773	revealed	_	_	_	_
9-4	774-778	that	_	_	_	_
9-5	779-782	the	abstract[59]	giv[59]	coref	8-4[0_59]
9-6	783-790	disease	abstract[59]	giv[59]	_	_
9-7	791-799	reoccurs	_	_	_	_
9-8	800-804	when	_	_	_	_
9-9	805-813	pancreas	object	new	_	_
9-10	814-818	fail	_	_	_	_
9-11	819-821	to	_	_	_	_
9-12	822-828	supply	_	_	_	_
9-13	829-832	the	abstract[61]	new[61]	coref	10-16[67_61]
9-14	833-843	peripheral	abstract[61]	new[61]	_	_
9-15	844-848	need	abstract[61]	new[61]	_	_
9-16	849-852	for	abstract[61]	new[61]	_	_
9-17	853-860	insulin	abstract[61]|substance	new[61]|new	coref	10-13
9-18	861-865	that	abstract[61]	new[61]	_	_
9-19	866-869	the	abstract[61]|object[63]	new[61]|new[63]	_	_
9-20	870-874	body	abstract[61]|object[63]	new[61]|new[63]	_	_
9-21	875-880	needs	abstract[61]	new[61]	_	_
9-22	881-882	.	_	_	_	_

#Text=According to Lício Velloso , as long as the pancreas can produce insulin to maintain this need , the blood glucose level remains stable - close to 80 , 90 , expected for a healthy person .
10-1	883-892	According	_	_	_	_
10-2	893-895	to	_	_	_	_
10-3	896-901	Lício	person[64]	giv[64]	coref	23-3[164_64]
10-4	902-909	Velloso	person[64]	giv[64]	_	_
10-5	910-911	,	_	_	_	_
10-6	912-914	as	_	_	_	_
10-7	915-919	long	_	_	_	_
10-8	920-922	as	_	_	_	_
10-9	923-926	the	object[65]	new[65]	_	_
10-10	927-935	pancreas	object[65]	new[65]	_	_
10-11	936-939	can	_	_	_	_
10-12	940-947	produce	_	_	_	_
10-13	948-955	insulin	substance	giv	coref	11-18
10-14	956-958	to	_	_	_	_
10-15	959-967	maintain	_	_	_	_
10-16	968-972	this	abstract[67]	giv[67]	_	_
10-17	973-977	need	abstract[67]	giv[67]	_	_
10-18	978-979	,	_	_	_	_
10-19	980-983	the	abstract[70]	new[70]	_	_
10-20	984-989	blood	substance|substance[69]|abstract[70]	new|new[69]|new[70]	coref|coref	11-8[75_69]|22-38[159_0]
10-21	990-997	glucose	substance[69]|abstract[70]	new[69]|new[70]	_	_
10-22	998-1003	level	abstract[70]	new[70]	_	_
10-23	1004-1011	remains	_	_	_	_
10-24	1012-1018	stable	_	_	_	_
10-25	1019-1020	-	_	_	_	_
10-26	1021-1026	close	abstract[71]	new[71]	_	_
10-27	1027-1029	to	abstract[71]	new[71]	_	_
10-28	1030-1032	80	abstract[71]	new[71]	_	_
10-29	1033-1034	,	_	_	_	_
10-30	1035-1037	90	abstract[72]	new[72]	ana	11-4[0_72]
10-31	1038-1039	,	abstract[72]	new[72]	_	_
10-32	1040-1048	expected	abstract[72]	new[72]	_	_
10-33	1049-1052	for	abstract[72]	new[72]	_	_
10-34	1053-1054	a	abstract[72]|person[73]	new[72]|new[73]	_	_
10-35	1055-1062	healthy	abstract[72]|person[73]	new[72]|new[73]	_	_
10-36	1063-1069	person	abstract[72]|person[73]	new[72]|new[73]	_	_
10-37	1070-1071	.	_	_	_	_

#Text=But , when it does fail , the glucose rises , which makes a patient dependent on insulin .
11-1	1072-1075	But	_	_	_	_
11-2	1076-1077	,	_	_	_	_
11-3	1078-1082	when	_	_	_	_
11-4	1083-1085	it	abstract	giv	_	_
11-5	1086-1090	does	_	_	_	_
11-6	1091-1095	fail	_	_	_	_
11-7	1096-1097	,	_	_	_	_
11-8	1098-1101	the	substance[75]	giv[75]	coref	20-20[132_75]
11-9	1102-1109	glucose	substance[75]	giv[75]	_	_
11-10	1110-1115	rises	_	_	_	_
11-11	1116-1117	,	_	_	_	_
11-12	1118-1123	which	_	_	_	_
11-13	1124-1129	makes	_	_	_	_
11-14	1130-1131	a	person[76]	new[76]	_	_
11-15	1132-1139	patient	person[76]	new[76]	_	_
11-16	1140-1149	dependent	_	_	_	_
11-17	1150-1152	on	_	_	_	_
11-18	1153-1160	insulin	substance	giv	coref	15-22
11-19	1161-1162	.	_	_	_	_

#Text=This dependency can result into hyperinsulinemic hypoglycemia , according to Velloso .
12-1	1163-1167	This	abstract[78]	new[78]	_	_
12-2	1168-1178	dependency	abstract[78]	new[78]	_	_
12-3	1179-1182	can	_	_	_	_
12-4	1183-1189	result	abstract	new	coref|none	14-2[88_0]|12-4[0_88]
12-5	1190-1194	into	_	_	_	_
12-6	1195-1211	hyperinsulinemic	abstract[79]	new[79]	_	_
12-7	1212-1224	hypoglycemia	abstract[79]	new[79]	_	_
12-8	1225-1226	,	_	_	_	_
12-9	1227-1236	according	_	_	_	_
12-10	1237-1239	to	_	_	_	_
12-11	1240-1247	Velloso	person	new	coref	13-2[81_0]
12-12	1248-1249	.	_	_	_	_

#Text=Under Velloso 's guidance , Souza had studied alpha protein and injected it with an insulin-producing cell .
13-1	1250-1255	Under	_	_	_	_
13-2	1256-1263	Velloso	person[81]|abstract[82]	giv[81]|new[82]	ana	13-13[0_82]
13-3	1264-1266	's	person[81]|abstract[82]	giv[81]|new[82]	_	_
13-4	1267-1275	guidance	abstract[82]	new[82]	_	_
13-5	1276-1277	,	_	_	_	_
13-6	1278-1283	Souza	person	giv	_	_
13-7	1284-1287	had	_	_	_	_
13-8	1288-1295	studied	_	_	_	_
13-9	1296-1301	alpha	object|substance[85]	new|new[85]	coref|coref	15-18|15-18[100_85]
13-10	1302-1309	protein	substance[85]	new[85]	_	_
13-11	1310-1313	and	_	_	_	_
13-12	1314-1322	injected	_	_	_	_
13-13	1323-1325	it	abstract	giv	_	_
13-14	1326-1330	with	_	_	_	_
13-15	1331-1333	an	object[87]	new[87]	_	_
13-16	1334-1351	insulin-producing	object[87]	new[87]	_	_
13-17	1352-1356	cell	object[87]	new[87]	_	_
13-18	1357-1358	.	_	_	_	_

#Text=While the result did n't yield a major breakthrough , it opened a possibility of developing a drug that would reduce the action of PPARGC1A .
14-1	1359-1364	While	_	_	_	_
14-2	1365-1368	the	abstract[88]	new[88]	_	_
14-3	1369-1375	result	abstract[88]	new[88]	_	_
14-4	1376-1379	did	_	_	_	_
14-5	1380-1383	n't	_	_	_	_
14-6	1384-1389	yield	_	_	_	_
14-7	1390-1391	a	event[89]	new[89]	ana	14-11[0_89]
14-8	1392-1397	major	event[89]	new[89]	_	_
14-9	1398-1410	breakthrough	event[89]	new[89]	_	_
14-10	1411-1412	,	_	_	_	_
14-11	1413-1415	it	event	giv	_	_
14-12	1416-1422	opened	_	_	_	_
14-13	1423-1424	a	abstract[91]	new[91]	_	_
14-14	1425-1436	possibility	abstract[91]	new[91]	_	_
14-15	1437-1439	of	abstract[91]	new[91]	_	_
14-16	1440-1450	developing	abstract[91]	new[91]	_	_
14-17	1451-1452	a	abstract[91]|substance[92]	new[91]|new[92]	_	_
14-18	1453-1457	drug	abstract[91]|substance[92]	new[91]|new[92]	_	_
14-19	1458-1462	that	abstract[91]|substance[92]	new[91]|new[92]	_	_
14-20	1463-1468	would	abstract[91]|substance[92]	new[91]|new[92]	_	_
14-21	1469-1475	reduce	abstract[91]|substance[92]	new[91]|new[92]	_	_
14-22	1476-1479	the	abstract[91]|substance[92]|abstract[93]	new[91]|new[92]|new[93]	ana	16-4[0_93]
14-23	1480-1486	action	abstract[91]|substance[92]|abstract[93]	new[91]|new[92]|new[93]	_	_
14-24	1487-1489	of	abstract[91]|substance[92]|abstract[93]	new[91]|new[92]|new[93]	_	_
14-25	1490-1498	PPARGC1A	abstract[91]|substance[92]|abstract[93]|abstract	new[91]|new[92]|new[93]|new	ana	15-11
14-26	1499-1500	.	_	_	_	_

#Text=During the trials , which the duo conducted revealed that it does indeed reduces the production of alpha protein while increases insulin production .
15-1	1501-1507	During	_	_	_	_
15-2	1508-1511	the	event[95]	new[95]	_	_
15-3	1512-1518	trials	event[95]	new[95]	_	_
15-4	1519-1520	,	event[95]	new[95]	_	_
15-5	1521-1526	which	event[95]	new[95]	_	_
15-6	1527-1530	the	event[95]|person[96]	new[95]|new[96]	ana	17-5[0_96]
15-7	1531-1534	duo	event[95]|person[96]	new[95]|new[96]	_	_
15-8	1535-1544	conducted	event[95]	new[95]	_	_
15-9	1545-1553	revealed	_	_	_	_
15-10	1554-1558	that	_	_	_	_
15-11	1559-1561	it	abstract	giv	_	_
15-12	1562-1566	does	_	_	_	_
15-13	1567-1573	indeed	_	_	_	_
15-14	1574-1581	reduces	_	_	_	_
15-15	1582-1585	the	abstract[98]	new[98]	coref	15-22[102_98]
15-16	1586-1596	production	abstract[98]	new[98]	_	_
15-17	1597-1599	of	abstract[98]	new[98]	_	_
15-18	1600-1605	alpha	abstract[98]|object|substance[100]	new[98]|giv|giv[100]	_	_
15-19	1606-1613	protein	abstract[98]|substance[100]	new[98]|giv[100]	_	_
15-20	1614-1619	while	_	_	_	_
15-21	1620-1629	increases	_	_	_	_
15-22	1630-1637	insulin	substance|abstract[102]	giv|giv[102]	coref|coref	16-6|16-6[105_102]
15-23	1638-1648	production	abstract[102]	giv[102]	_	_
15-24	1649-1650	.	_	_	_	_

#Text=Not only did it increase insulin production , but it also decrease diabetes occurrence . [ 4 ]
16-1	1651-1654	Not	_	_	_	_
16-2	1655-1659	only	_	_	_	_
16-3	1660-1663	did	_	_	_	_
16-4	1664-1666	it	abstract	giv	ana	16-10
16-5	1667-1675	increase	_	_	_	_
16-6	1676-1683	insulin	substance|abstract[105]	giv|giv[105]	_	_
16-7	1684-1694	production	abstract[105]	giv[105]	_	_
16-8	1695-1696	,	_	_	_	_
16-9	1697-1700	but	_	_	_	_
16-10	1701-1703	it	abstract	giv	coref	21-11[140_0]
16-11	1704-1708	also	_	_	_	_
16-12	1709-1717	decrease	_	_	_	_
16-13	1718-1726	diabetes	abstract|event[108]	giv|new[108]	_	_
16-14	1727-1737	occurrence	event[108]	new[108]	_	_
16-15	1738-1739	.	_	_	_	_
16-16	1740-1741	[	_	_	_	_
16-17	1742-1743	4	abstract	new	_	_
16-18	1744-1745	]	_	_	_	_

#Text=For two years , he and Marciane Milanski , a nutritionist , had studied obesity in rats .
17-1	1746-1749	For	_	_	_	_
17-2	1750-1753	two	time[110]	new[110]	_	_
17-3	1754-1759	years	time[110]	new[110]	_	_
17-4	1760-1761	,	_	_	_	_
17-5	1762-1764	he	person	giv	_	_
17-6	1765-1768	and	_	_	_	_
17-7	1769-1777	Marciane	person[112]	new[112]	appos	17-10[113_112]
17-8	1778-1786	Milanski	person[112]	new[112]	_	_
17-9	1787-1788	,	_	_	_	_
17-10	1789-1790	a	person[113]	giv[113]	_	_
17-11	1791-1803	nutritionist	person[113]	giv[113]	_	_
17-12	1804-1805	,	_	_	_	_
17-13	1806-1809	had	_	_	_	_
17-14	1810-1817	studied	_	_	_	_
17-15	1818-1825	obesity	abstract	giv	ana	18-5
17-16	1826-1828	in	_	_	_	_
17-17	1829-1833	rats	animal	new	_	_
17-18	1834-1835	.	_	_	_	_

#Text=During the study , it was suggested that it is possible to make brain control liver in order to maintain glycemic balance .
18-1	1836-1842	During	_	_	_	_
18-2	1843-1846	the	abstract[116]	giv[116]	coref	24-2[169_116]
18-3	1847-1852	study	abstract[116]	giv[116]	_	_
18-4	1853-1854	,	_	_	_	_
18-5	1855-1857	it	abstract	giv	ana	18-9
18-6	1858-1861	was	_	_	_	_
18-7	1862-1871	suggested	_	_	_	_
18-8	1872-1876	that	_	_	_	_
18-9	1877-1879	it	abstract	giv	coref	29-24
18-10	1880-1882	is	_	_	_	_
18-11	1883-1891	possible	_	_	_	_
18-12	1892-1894	to	_	_	_	_
18-13	1895-1899	make	_	_	_	_
18-14	1900-1905	brain	object	new	_	_
18-15	1906-1913	control	_	_	_	_
18-16	1914-1919	liver	object	new	ana	19-2
18-17	1920-1922	in	_	_	_	_
18-18	1923-1928	order	_	_	_	_
18-19	1929-1931	to	_	_	_	_
18-20	1932-1940	maintain	_	_	_	_
18-21	1941-1949	glycemic	abstract[121]	new[121]	_	_
18-22	1950-1957	balance	abstract[121]	new[121]	_	_
18-23	1958-1959	.	_	_	_	_

#Text=When it does happen , the hypothalamus becomes the main actor of this mechanism .
19-1	1960-1964	When	_	_	_	_
19-2	1965-1967	it	object	giv	coref	25-30
19-3	1968-1972	does	_	_	_	_
19-4	1973-1979	happen	_	_	_	_
19-5	1980-1981	,	_	_	_	_
19-6	1982-1985	the	abstract[123]	new[123]	coref	20-33[134_123]
19-7	1986-1998	hypothalamus	abstract[123]	new[123]	_	_
19-8	1999-2006	becomes	_	_	_	_
19-9	2007-2010	the	person[124]	new[124]	ana	20-6[0_124]
19-10	2011-2015	main	person[124]	new[124]	_	_
19-11	2016-2021	actor	person[124]	new[124]	_	_
19-12	2022-2024	of	person[124]	new[124]	_	_
19-13	2025-2029	this	person[124]|abstract[125]	new[124]|new[125]	coref	20-10[129_125]
19-14	2030-2039	mechanism	person[124]|abstract[125]	new[124]|new[125]	_	_
19-15	2040-2041	.	_	_	_	_

#Text=The research , along with his comment : " The mechanism described by this research shows that control of high glucose in fasting is done , at least in part , by the hypothalamus .
20-1	2042-2045	The	abstract[126]	giv[126]	coref	20-14[130_126]
20-2	2046-2054	research	abstract[126]	giv[126]	_	_
20-3	2055-2056	,	abstract[126]	giv[126]	_	_
20-4	2057-2062	along	abstract[126]|abstract[128]	giv[126]|new[128]	_	_
20-5	2063-2067	with	abstract[126]|abstract[128]	giv[126]|new[128]	_	_
20-6	2068-2071	his	abstract[126]|person|abstract[128]	giv[126]|giv|new[128]	_	_
20-7	2072-2079	comment	abstract[126]|abstract[128]	giv[126]|new[128]	_	_
20-8	2080-2081	:	_	_	_	_
20-9	2082-2083	"	_	_	_	_
20-10	2084-2087	The	abstract[129]	giv[129]	_	_
20-11	2088-2097	mechanism	abstract[129]	giv[129]	_	_
20-12	2098-2107	described	abstract[129]	giv[129]	_	_
20-13	2108-2110	by	abstract[129]	giv[129]	_	_
20-14	2111-2115	this	abstract[129]|abstract[130]	giv[129]|giv[130]	_	_
20-15	2116-2124	research	abstract[129]|abstract[130]	giv[129]|giv[130]	_	_
20-16	2125-2130	shows	_	_	_	_
20-17	2131-2135	that	_	_	_	_
20-18	2136-2143	control	abstract[131]	new[131]	_	_
20-19	2144-2146	of	abstract[131]	new[131]	_	_
20-20	2147-2151	high	abstract[131]|substance[132]	new[131]|giv[132]	_	_
20-21	2152-2159	glucose	abstract[131]|substance[132]	new[131]|giv[132]	_	_
20-22	2160-2162	in	abstract[131]|substance[132]	new[131]|giv[132]	_	_
20-23	2163-2170	fasting	abstract[131]|substance[132]|event	new[131]|giv[132]|new	_	_
20-24	2171-2173	is	_	_	_	_
20-25	2174-2178	done	_	_	_	_
20-26	2179-2180	,	_	_	_	_
20-27	2181-2183	at	_	_	_	_
20-28	2184-2189	least	_	_	_	_
20-29	2190-2192	in	_	_	_	_
20-30	2193-2197	part	_	_	_	_
20-31	2198-2199	,	_	_	_	_
20-32	2200-2202	by	_	_	_	_
20-33	2203-2206	the	abstract[134]	giv[134]	ana	21-1[0_134]
20-34	2207-2219	hypothalamus	abstract[134]	giv[134]	_	_
20-35	2220-2221	.	_	_	_	_

#Text=This reinforces our suspicion that the development of drugs with action in the central nervous system should be interesting for the treatment of diabetes " were published in the American Journal of Deabetes in 2012 . [ 5 ]
21-1	2222-2226	This	abstract	giv	coref	22-45[161_0]
21-2	2227-2237	reinforces	_	_	_	_
21-3	2238-2241	our	person|abstract[137]	acc|new[137]	_	_
21-4	2242-2251	suspicion	abstract[137]	new[137]	_	_
21-5	2252-2256	that	abstract[137]	new[137]	_	_
21-6	2257-2260	the	abstract[137]|event[138]	new[137]|new[138]	_	_
21-7	2261-2272	development	abstract[137]|event[138]	new[137]|new[138]	_	_
21-8	2273-2275	of	abstract[137]|event[138]	new[137]|new[138]	_	_
21-9	2276-2281	drugs	abstract[137]|event[138]|substance[139]	new[137]|new[138]|new[139]	_	_
21-10	2282-2286	with	abstract[137]|event[138]|substance[139]	new[137]|new[138]|new[139]	_	_
21-11	2287-2293	action	abstract[137]|event[138]|substance[139]|abstract[140]	new[137]|new[138]|new[139]|giv[140]	_	_
21-12	2294-2296	in	abstract[137]|event[138]|substance[139]|abstract[140]	new[137]|new[138]|new[139]|giv[140]	_	_
21-13	2297-2300	the	abstract[137]|event[138]|substance[139]|abstract[140]|abstract[141]	new[137]|new[138]|new[139]|giv[140]|new[141]	_	_
21-14	2301-2308	central	abstract[137]|event[138]|substance[139]|abstract[140]|abstract[141]	new[137]|new[138]|new[139]|giv[140]|new[141]	_	_
21-15	2309-2316	nervous	abstract[137]|event[138]|substance[139]|abstract[140]|abstract[141]	new[137]|new[138]|new[139]|giv[140]|new[141]	_	_
21-16	2317-2323	system	abstract[137]|event[138]|substance[139]|abstract[140]|abstract[141]	new[137]|new[138]|new[139]|giv[140]|new[141]	_	_
21-17	2324-2330	should	abstract[137]	new[137]	_	_
21-18	2331-2333	be	abstract[137]	new[137]	_	_
21-19	2334-2345	interesting	abstract[137]	new[137]	_	_
21-20	2346-2349	for	abstract[137]	new[137]	_	_
21-21	2350-2353	the	abstract[137]|abstract[142]	new[137]|new[142]	_	_
21-22	2354-2363	treatment	abstract[137]|abstract[142]	new[137]|new[142]	_	_
21-23	2364-2366	of	abstract[137]|abstract[142]	new[137]|new[142]	_	_
21-24	2367-2375	diabetes	abstract[137]|abstract[142]|abstract	new[137]|new[142]|giv	_	_
21-25	2376-2377	"	abstract[137]	new[137]	_	_
21-26	2378-2382	were	abstract[137]	new[137]	_	_
21-27	2383-2392	published	abstract[137]	new[137]	_	_
21-28	2393-2395	in	abstract[137]	new[137]	_	_
21-29	2396-2399	the	abstract[137]|organization[144]	new[137]|new[144]	_	_
21-30	2400-2408	American	abstract[137]|organization[144]	new[137]|new[144]	_	_
21-31	2409-2416	Journal	abstract[137]|organization[144]	new[137]|new[144]	_	_
21-32	2417-2419	of	abstract[137]|organization[144]	new[137]|new[144]	_	_
21-33	2420-2428	Deabetes	abstract[137]|organization[144]|person	new[137]|new[144]|new	ana	22-5
21-34	2429-2431	in	abstract[137]	new[137]	_	_
21-35	2432-2436	2012	abstract[137]|time	new[137]|new	_	_
21-36	2437-2438	.	_	_	_	_
21-37	2439-2440	[	_	_	_	_
21-38	2441-2442	5	abstract	new	_	_
21-39	2443-2444	]	_	_	_	_

#Text=From 2005 to 2007 he had studied human diet , and , according to him , the studies of various groups have shown that a diet rich in simple carbohydrates , can also increase lipid levels in the blood and indirectly promote inflammation in the hypothalamus . [ 3 ]
22-1	2445-2449	From	_	_	_	_
22-2	2450-2454	2005	time	new	_	_
22-3	2455-2457	to	_	_	_	_
22-4	2458-2462	2007	time	new	_	_
22-5	2463-2465	he	person	giv	ana	22-15
22-6	2466-2469	had	_	_	_	_
22-7	2470-2477	studied	_	_	_	_
22-8	2478-2483	human	abstract[151]	new[151]	coref	22-25[155_151]
22-9	2484-2488	diet	abstract[151]	new[151]	_	_
22-10	2489-2490	,	_	_	_	_
22-11	2491-2494	and	_	_	_	_
22-12	2495-2496	,	_	_	_	_
22-13	2497-2506	according	_	_	_	_
22-14	2507-2509	to	_	_	_	_
22-15	2510-2513	him	person	giv	_	_
22-16	2514-2515	,	_	_	_	_
22-17	2516-2519	the	abstract[153]	new[153]	_	_
22-18	2520-2527	studies	abstract[153]	new[153]	_	_
22-19	2528-2530	of	abstract[153]	new[153]	_	_
22-20	2531-2538	various	abstract[153]|person[154]	new[153]|new[154]	ana	23-10[0_154]
22-21	2539-2545	groups	abstract[153]|person[154]	new[153]|new[154]	_	_
22-22	2546-2550	have	_	_	_	_
22-23	2551-2556	shown	_	_	_	_
22-24	2557-2561	that	_	_	_	_
22-25	2562-2563	a	abstract[155]	giv[155]	_	_
22-26	2564-2568	diet	abstract[155]	giv[155]	_	_
22-27	2569-2573	rich	abstract[155]	giv[155]	_	_
22-28	2574-2576	in	abstract[155]	giv[155]	_	_
22-29	2577-2583	simple	abstract[155]|substance[156]	giv[155]|new[156]	_	_
22-30	2584-2597	carbohydrates	abstract[155]|substance[156]	giv[155]|new[156]	_	_
22-31	2598-2599	,	_	_	_	_
22-32	2600-2603	can	_	_	_	_
22-33	2604-2608	also	_	_	_	_
22-34	2609-2617	increase	_	_	_	_
22-35	2618-2623	lipid	substance|abstract[158]	new|new[158]	_	_
22-36	2624-2630	levels	abstract[158]	new[158]	_	_
22-37	2631-2633	in	_	_	_	_
22-38	2634-2637	the	substance[159]	giv[159]	_	_
22-39	2638-2643	blood	substance[159]	giv[159]	_	_
22-40	2644-2647	and	_	_	_	_
22-41	2648-2658	indirectly	_	_	_	_
22-42	2659-2666	promote	_	_	_	_
22-43	2667-2679	inflammation	abstract[160]	new[160]	_	_
22-44	2680-2682	in	abstract[160]	new[160]	_	_
22-45	2683-2686	the	abstract[160]|abstract[161]	new[160]|giv[161]	_	_
22-46	2687-2699	hypothalamus	abstract[160]|abstract[161]	new[160]|giv[161]	_	_
22-47	2700-2701	.	_	_	_	_
22-48	2702-2703	[	_	_	_	_
22-49	2704-2705	3	abstract	giv	_	_
22-50	2706-2707	]	_	_	_	_

#Text=In 2018 Lício Velloso studied hunger strikes and divided them in three categories : Absolute , total and partial .
23-1	2708-2710	In	_	_	_	_
23-2	2711-2715	2018	time	new	coref	27-5
23-3	2716-2721	Lício	person[164]	giv[164]	ana	24-5[0_164]
23-4	2722-2729	Velloso	person[164]	giv[164]	_	_
23-5	2730-2737	studied	_	_	_	_
23-6	2738-2744	hunger	abstract|event[166]	new|new[166]	coref|coref	24-12|24-11[173_166]
23-7	2745-2752	strikes	event[166]	new[166]	_	_
23-8	2753-2756	and	_	_	_	_
23-9	2757-2764	divided	_	_	_	_
23-10	2765-2769	them	person	giv	_	_
23-11	2770-2772	in	_	_	_	_
23-12	2773-2778	three	abstract[168]	new[168]	_	_
23-13	2779-2789	categories	abstract[168]	new[168]	_	_
23-14	2790-2791	:	_	_	_	_
23-15	2792-2800	Absolute	_	_	_	_
23-16	2801-2802	,	_	_	_	_
23-17	2803-2808	total	_	_	_	_
23-18	2809-2812	and	_	_	_	_
23-19	2813-2820	partial	_	_	_	_
23-20	2821-2822	.	_	_	_	_

#Text=During the study , he suggested that people who do partial hunger strikes could have more severe consequences then those that have the absolute one .
24-1	2823-2829	During	_	_	_	_
24-2	2830-2833	the	abstract[169]	giv[169]	_	_
24-3	2834-2839	study	abstract[169]	giv[169]	_	_
24-4	2840-2841	,	_	_	_	_
24-5	2842-2844	he	person	giv	ana	24-20[175_0]
24-6	2845-2854	suggested	_	_	_	_
24-7	2855-2859	that	_	_	_	_
24-8	2860-2866	people	person[171]	new[171]	coref	26-10[189_171]
24-9	2867-2870	who	person[171]	new[171]	_	_
24-10	2871-2873	do	person[171]	new[171]	_	_
24-11	2874-2881	partial	person[171]|event[173]	new[171]|giv[173]	_	_
24-12	2882-2888	hunger	person[171]|abstract|event[173]	new[171]|giv|giv[173]	_	_
24-13	2889-2896	strikes	person[171]|event[173]	new[171]|giv[173]	_	_
24-14	2897-2902	could	_	_	_	_
24-15	2903-2907	have	_	_	_	_
24-16	2908-2912	more	abstract[174]	new[174]	_	_
24-17	2913-2919	severe	abstract[174]	new[174]	_	_
24-18	2920-2932	consequences	abstract[174]	new[174]	_	_
24-19	2933-2937	then	_	_	_	_
24-20	2938-2943	those	person[175]	giv[175]	_	_
24-21	2944-2948	that	person[175]	giv[175]	_	_
24-22	2949-2953	have	person[175]	giv[175]	_	_
24-23	2954-2957	the	person[175]|event[176]	giv[175]|new[176]	coref	25-5[177_176]
24-24	2958-2966	absolute	person[175]|event[176]	giv[175]|new[176]	_	_
24-25	2967-2970	one	person[175]|event[176]	giv[175]|new[176]	_	_
24-26	2971-2972	.	_	_	_	_

#Text=For example , in an absolute strike only kidneys and heart fails after 25 days of being on a strike , while strikers who preferred partial ended up with liver complications within 40 to 50 days after the strike .
25-1	2973-2976	For	_	_	_	_
25-2	2977-2984	example	_	_	_	_
25-3	2985-2986	,	_	_	_	_
25-4	2987-2989	in	_	_	_	_
25-5	2990-2992	an	event[177]	giv[177]	coref	25-19[181_177]
25-6	2993-3001	absolute	event[177]	giv[177]	_	_
25-7	3002-3008	strike	event[177]	giv[177]	_	_
25-8	3009-3013	only	object[178]	new[178]	_	_
25-9	3014-3021	kidneys	object[178]	new[178]	_	_
25-10	3022-3025	and	_	_	_	_
25-11	3026-3031	heart	object	new	coref	26-13[190_0]
25-12	3032-3037	fails	_	_	_	_
25-13	3038-3043	after	_	_	_	_
25-14	3044-3046	25	time[180]	new[180]	_	_
25-15	3047-3051	days	time[180]	new[180]	_	_
25-16	3052-3054	of	time[180]	new[180]	_	_
25-17	3055-3060	being	time[180]	new[180]	_	_
25-18	3061-3063	on	time[180]	new[180]	_	_
25-19	3064-3065	a	time[180]|event[181]	new[180]|giv[181]	coref	25-38[186_181]
25-20	3066-3072	strike	time[180]|event[181]	new[180]|giv[181]	_	_
25-21	3073-3074	,	_	_	_	_
25-22	3075-3080	while	_	_	_	_
25-23	3081-3089	strikers	person[182]	new[182]	_	_
25-24	3090-3093	who	person[182]	new[182]	_	_
25-25	3094-3103	preferred	person[182]	new[182]	_	_
25-26	3104-3111	partial	person[182]	new[182]	_	_
25-27	3112-3117	ended	_	_	_	_
25-28	3118-3120	up	_	_	_	_
25-29	3121-3125	with	_	_	_	_
25-30	3126-3131	liver	object|abstract[184]	giv|new[184]	_	_
25-31	3132-3145	complications	abstract[184]	new[184]	_	_
25-32	3146-3152	within	_	_	_	_
25-33	3153-3155	40	time[185]	new[185]	_	_
25-34	3156-3158	to	time[185]	new[185]	_	_
25-35	3159-3161	50	time[185]	new[185]	_	_
25-36	3162-3166	days	time[185]	new[185]	_	_
25-37	3167-3172	after	time[185]	new[185]	_	_
25-38	3173-3176	the	time[185]|event[186]	new[185]|giv[186]	ana	26-24[0_186]
25-39	3177-3183	strike	time[185]|event[186]	new[185]|giv[186]	_	_
25-40	3184-3185	.	_	_	_	_

#Text=In conclusion , what Dr. Velloso suggests is that people who have a weak heart should n't take too much liquid , otherwise it can lead to heart failure and even death . [ 6 ]
26-1	3186-3188	In	_	_	_	_
26-2	3189-3199	conclusion	abstract	new	_	_
26-3	3200-3201	,	_	_	_	_
26-4	3202-3206	what	_	_	_	_
26-5	3207-3210	Dr.	person[188]	new[188]	ana	27-6[0_188]
26-6	3211-3218	Velloso	person[188]	new[188]	_	_
26-7	3219-3227	suggests	_	_	_	_
26-8	3228-3230	is	_	_	_	_
26-9	3231-3235	that	_	_	_	_
26-10	3236-3242	people	person[189]	giv[189]	_	_
26-11	3243-3246	who	person[189]	giv[189]	_	_
26-12	3247-3251	have	person[189]	giv[189]	_	_
26-13	3252-3253	a	person[189]|object[190]	giv[189]|giv[190]	coref	26-28[0_190]
26-14	3254-3258	weak	person[189]|object[190]	giv[189]|giv[190]	_	_
26-15	3259-3264	heart	person[189]|object[190]	giv[189]|giv[190]	_	_
26-16	3265-3271	should	_	_	_	_
26-17	3272-3275	n't	_	_	_	_
26-18	3276-3280	take	_	_	_	_
26-19	3281-3284	too	substance[191]	new[191]	_	_
26-20	3285-3289	much	substance[191]	new[191]	_	_
26-21	3290-3296	liquid	substance[191]	new[191]	_	_
26-22	3297-3298	,	_	_	_	_
26-23	3299-3308	otherwise	_	_	_	_
26-24	3309-3311	it	event	giv	_	_
26-25	3312-3315	can	_	_	_	_
26-26	3316-3320	lead	_	_	_	_
26-27	3321-3323	to	_	_	_	_
26-28	3324-3329	heart	object|event[194]	giv|new[194]	_	_
26-29	3330-3337	failure	event[194]	new[194]	_	_
26-30	3338-3341	and	_	_	_	_
26-31	3342-3346	even	event[195]	new[195]	_	_
26-32	3347-3352	death	event[195]	new[195]	_	_
26-33	3353-3354	.	_	_	_	_
26-34	3355-3356	[	_	_	_	_
26-35	3357-3358	6	abstract	new	_	_
26-36	3359-3360	]	_	_	_	_

#Text=On October 30 , 2018 he appeared on an interview with Paulo Saldiva of Science and Health program of the Futura Chanel . [ 7 ]
27-1	3361-3363	On	_	_	_	_
27-2	3364-3371	October	time[197]	new[197]	_	_
27-3	3372-3374	30	time[197]	new[197]	_	_
27-4	3375-3376	,	time[197]	new[197]	_	_
27-5	3377-3381	2018	time[197]|time	new[197]|giv	_	_
27-6	3382-3384	he	person	giv	ana	29-1
27-7	3385-3393	appeared	_	_	_	_
27-8	3394-3396	on	_	_	_	_
27-9	3397-3399	an	event[200]	new[200]	_	_
27-10	3400-3409	interview	event[200]	new[200]	_	_
27-11	3410-3414	with	event[200]	new[200]	_	_
27-12	3415-3420	Paulo	event[200]|person[201]	new[200]|new[201]	_	_
27-13	3421-3428	Saldiva	event[200]|person[201]	new[200]|new[201]	_	_
27-14	3429-3431	of	event[200]|person[201]	new[200]|new[201]	_	_
27-15	3432-3439	Science	event[200]|person[201]|abstract|abstract[204]	new[200]|new[201]|new|new[204]	_	_
27-16	3440-3443	and	event[200]|person[201]|abstract[204]	new[200]|new[201]|new[204]	_	_
27-17	3444-3450	Health	event[200]|person[201]|abstract|abstract[204]	new[200]|new[201]|new|new[204]	_	_
27-18	3451-3458	program	event[200]|person[201]|abstract[204]	new[200]|new[201]|new[204]	_	_
27-19	3459-3461	of	event[200]|person[201]|abstract[204]	new[200]|new[201]|new[204]	_	_
27-20	3462-3465	the	event[200]|person[201]|abstract[204]|organization[205]	new[200]|new[201]|new[204]|new[205]	_	_
27-21	3466-3472	Futura	event[200]|person[201]|abstract[204]|organization[205]	new[200]|new[201]|new[204]|new[205]	_	_
27-22	3473-3479	Chanel	event[200]|person[201]|abstract[204]|organization[205]	new[200]|new[201]|new[204]|new[205]	_	_
27-23	3480-3481	.	_	_	_	_
27-24	3482-3483	[	_	_	_	_
27-25	3484-3485	7	abstract	new	_	_
27-26	3486-3487	]	_	_	_	_

#Text=Editorial work
28-1	3488-3497	Editorial	abstract[207]	new[207]	_	_
28-2	3498-3502	work	abstract[207]	new[207]	_	_

#Text=He is a former member of the editorial board of Clinical Endocrinology and current member of the editorial board of International Journal of Obesity . [ 8 ]
29-1	3503-3505	He	person	giv	coref	29-3[209_0]
29-2	3506-3508	is	_	_	_	_
29-3	3509-3510	a	person[209]|person[210]	giv[209]|giv[210]	coref	29-3[210_209]
29-4	3511-3517	former	person[209]|person[210]	giv[209]|giv[210]	_	_
29-5	3518-3524	member	person[209]|person[210]	giv[209]|giv[210]	_	_
29-6	3525-3527	of	person[209]|person[210]	giv[209]|giv[210]	_	_
29-7	3528-3531	the	person[209]|person[210]|organization[211]	giv[209]|giv[210]|new[211]	_	_
29-8	3532-3541	editorial	person[209]|person[210]|organization[211]	giv[209]|giv[210]|new[211]	_	_
29-9	3542-3547	board	person[209]|person[210]|organization[211]	giv[209]|giv[210]|new[211]	_	_
29-10	3548-3550	of	person[209]|person[210]|organization[211]	giv[209]|giv[210]|new[211]	_	_
29-11	3551-3559	Clinical	person[209]|person[210]|organization[211]|abstract[212]	giv[209]|giv[210]|new[211]|new[212]	_	_
29-12	3560-3573	Endocrinology	person[209]|person[210]|organization[211]|abstract[212]	giv[209]|giv[210]|new[211]|new[212]	_	_
29-13	3574-3577	and	person[210]	giv[210]	_	_
29-14	3578-3585	current	person[210]|person[213]	giv[210]|new[213]	_	_
29-15	3586-3592	member	person[210]|person[213]	giv[210]|new[213]	_	_
29-16	3593-3595	of	person[210]|person[213]	giv[210]|new[213]	_	_
29-17	3596-3599	the	person[210]|person[213]|organization[214]	giv[210]|new[213]|new[214]	_	_
29-18	3600-3609	editorial	person[210]|person[213]|organization[214]	giv[210]|new[213]|new[214]	_	_
29-19	3610-3615	board	person[210]|person[213]|organization[214]	giv[210]|new[213]|new[214]	_	_
29-20	3616-3618	of	person[210]|person[213]|organization[214]	giv[210]|new[213]|new[214]	_	_
29-21	3619-3632	International	person[210]|person[213]|organization[214]|organization[215]	giv[210]|new[213]|new[214]|new[215]	_	_
29-22	3633-3640	Journal	person[210]|person[213]|organization[214]|organization[215]	giv[210]|new[213]|new[214]|new[215]	_	_
29-23	3641-3643	of	person[210]|person[213]|organization[214]|organization[215]	giv[210]|new[213]|new[214]|new[215]	_	_
29-24	3644-3651	Obesity	person[210]|person[213]|organization[214]|organization[215]|abstract	giv[210]|new[213]|new[214]|new[215]|giv	_	_
29-25	3652-3653	.	_	_	_	_
29-26	3654-3655	[	_	_	_	_
29-27	3656-3657	8	abstract	new	_	_
29-28	3658-3659	]	_	_	_	_
